Navigation Links
Translating the conversation between the brain and blood vessels
Date:4/21/2009

BETHESDA, Md. (April 21, 2009) When Francois Abboud began his work at the University of Iowa in 1960, little was known about the constant physiological chatter between the brain and the blood vessels. His research since has helped unravel how this chatter adjusts blood pressure and blood flow to meet the body's constantly changing demands.

The work has already led to clinical advances, and more may be on the way: Dr. Abboud defined the identity of a sensor in the nerve endings in the carotid artery in the neck that rapidly lowers blood pressure when stimulated. A clinical trial is now underway to see if people who are hypertensive can lower their blood pressure by using a pacemaker-like device that stimulates the nerve endings in the blood vessels.

Ann M. Schreihofer focuses on the role the brain plays in increasing sympathetic nervous activity, which contributes to many forms of hypertension (high blood pressure). Her Medical College of Georgia laboratory studies the links between conditions such as obesity and the chronic intermittent hypoxia that happens in sleep apnea and chronic activation of the sympathetic nervous system.

"We're studying why people who are obese become hypertensive," Dr. Schreihofer said of one aspect of her work. "We believe this is due to something about the obese state: We don't know what that is, but we're starting to rule things out." Indeed, the Schreihofer laboratory has already answered one question: Does hypertension occur because the brain loses its ability to sense that the blood vessels are stretching under high pressure? In a study with obese rats, they found the rats' brains could sense the stretch but still became hypertensive, eliminating that mechanism as a possibility.

APS recognizes important research

The American Physiological Society (APS) presented its highest award, the Walter B. Cannon Award, to Dr. Abboud. He is the 27th recipient of the Cannon Award, which goes to an outstanding scientist, and delivered the Walter B. Cannon Physiology in Perspective lecture on April 18. The lecture is part of the 122nd annual meeting of the APS, which is part of Experimental Biology 2009.

The Society has awarded Dr. Schreihofer the Henry Pickering Bowditch Memorial Award for early-career achievement. She is the 53rd recipient of the award, which goes to a scientist younger than 42 years whose accomplishments are both original and outstanding. It is the Society's second-highest award. Dr. Schreihofer presented the Bowditch lecture on April 19, at the APS session of Experimental Biology 2009.

Distinguished careers

Dr. Abboud is the Edith King Pearson Chair in Cardiovascular Research and director of the Cardiovascular Research Center at the Carver College of Medicine at the University of Iowa. He is a past-president of the American Heart Association, a former editor of Physiology in Medicine (Annals of Internal Medicine) and past president of the Association of American Physicians. He is a member of the National Academies of Science and the American Academy of Arts and Sciences.

Dr. Schreihofer has won three previous awards from The American Physiological Society. She established her own laboratory at the Medical College of Georgia in 2001. Still at the beginning of her career, she has already co-authored more than 35 studies in peer-reviewed journals, including the Journal of Physiology, Journal of Neuroscience and the American Journal of Physiology.

Dr. Abboud has helped discover how the brain uses hormones to orchestrate blood flow to different parts of the body. This helped explain how the brain sends blood to the gastrointestinal tract after eating, but redirects it to the heart and muscles if we start running, for example.

Recently, his team has been looking at which genes regulate ion channels, microscopic gates that move chemicals in and out of cells, and that play a role in the signaling between the brain and the blood vessels. In experiments with animals, Dr. Abboud and his colleagues deleted one specific ion channel and found that the animals developed high blood pressure. Work is now planned to develop a blood test to identify patients who suffer high blood pressure or heart failure because of a problem with the gene that regulates the channel, Dr. Abboud said.

New work underway

Dr. Schreihofer's laboratory has identified neurotransmitters that are at work in the brain stem that regulate sympathetic nervous activity. Neurotransmitters relay signals from one nerve cell to another, allowing nerve cells to 'talk' to each other. The Schreihofer laboratory will:

  • Test the hypothesis that neurons that inhibit sympathetic activity lose their ability to do so. This may allow the neurons that stimulate sympathetic activity to get the upper hand, which leads to hypertension.

  • Study how the brain stem neurons that regulate breathing impact neurons that control blood pressure. The neurons that integrate these systems are in very close proximity in the ventral lateral medulla and play a role in affecting both breathing and blood pressure. This connection is intriguing because it raises the possibility that improving respiratory function could be a way to reduce the sympathetic activity that leads to obesity and hypertension.


'/>"/>

Contact: Christine Guilfoy
cguilfoy@the-aps.org
301-634-7253
American Physiological Society
Source:Eurekalert

Related biology news :

1. Researchers discover link between schizophrenia and diabetes
2. Exploring the dynamic relationship between health and environment
3. It takes a genome: How a clash between our genes and modern life is making us sick
4. Plasminogen activator inhibitor type-1 -- a potential link between heart failure and diabetes
5. Link between unexploded munitions in oceans and cancer-causing toxins determined
6. Researchers shed new light on connection between brain and loneliness
7. Genetic differences between yeasts greater than those between humans and chimpanzees
8. Genetic study shows direct link between vitamin D and MS susceptibility gene
9. Genome Medicine: Bridging the gap between research and clinical practice
10. Is there a relationship between sleep-wake rhythm and diabetes?
11. Biologists discover link between CGG repeats in DNA and neurological disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... 27, 2017   Strategic Cyber Ventures , the ... led a $3.5 million investment in  Polarity , the ... Ventures is DC based and is led by cybersecurity ... . Ron Gula , also a longtime cybersecurity ... in this series A round of funding. This new ...
(Date:2/22/2017)... 2017 With the biometrics market to ... four technologies that innovative and agile startups must ... in the changing competitive landscape: multifactor authentication (MFA), ... "Companies can no longer afford to ... Dimitrios Pavlakis , Industry Analyst at ABI ...
(Date:2/16/2017)... FRANCISCO , Feb. 16, 2017  Genos, ... today announced that it has received Laboratory Accreditation ... CAP Accreditation is presented to laboratories that meet ... who demonstrate scientifically rigorous processes. "Genos ... excellence in laboratory practices. We,re honored to be ...
Breaking Biology News(10 mins):
(Date:3/28/2017)... ... March 28, 2017 , ... T3D ... a new orally administered treatment for Alzheimer’s disease (AD), today announced that Dr. ... “As we seek to uniquely treat the metabolic dysfunctions inherent in Alzheimer’s disease ...
(Date:3/27/2017)... March 27, 2017 Roka Bioscience, Inc. (NASDAQ: ROKA), ... for the detection of foodborne pathogens,  today announced that ... Company Spring 2017 Convention on March 29 at 9:50am ET. ... Marquis. About Roka Bioscience ... Roka Bioscience is ...
(Date:3/27/2017)... Properties (NYSE: CUZ ) announced today that Amgen, ... 10-year, approximately 125,000 square-foot lease at Corporate Center, a 1,224,000 ... submarket of Tampa, FL. ... for their new location in Tampa ," ... of Cousins Properties. "Amgen is a cutting-edge global company at ...
(Date:3/27/2017)... 2017 Infectex Ltd., a Russian portfolio company of Maxwell Biotech ... SQ109 added to the standard drug therapy regimen in patients with multidrug-resistant pulmonary tuberculosis ... ( USA ) and the US National Institutes of Health. ... ... Fund Logo ...
Breaking Biology Technology: